Cohort 8.0 founders Garland Surgical have been awarded up to €1.4 million in grant funding by Malta Enterprise.
We are incredibly excited to bring you some fantastic news from Cohort 8.0 founders Garland Surgical. Garland, who are developing a revolutionary longer-lasting hip replacement - the MaltaHip have been approved for up to €1.4 million in grant funding by Malta Enterprise - the economic development agency for Malta.
Aimed at helping Garland push the MaltaHip towards regulatory approval and market launch, Malta Enterprise's grant offering also includes laboratory space at the Malta Life Sciences Park, key for further research and development.
We are tremendously proud to see the confidence and support that has been generated in the MaltaHip project and look forward to seeing the continued journey towards fully-fledged public use.
To read the full LinkedIn post from Garland Surgical, use the link here.
08 Jul 2026 | Cohort Successes
CEO Adrian Burden of BetaDen alumni BlockMark Technologies attended the formal launch of the Cyber...
06 Jul 2026 | Cohort Successes
BetaDen Accelerate alumni Garland Surgical & CORZ have both been nominated for the 2026 Innovation...
17 Jun 2026 | Cohort Successes
The Cwtch case, designed by Judy Jones of BetaDen Incubate Intake 6.0 has been featured in the BBC...









